Background A previous cohort research indicated that atazanavir (ATV), a protease inhibitor employed for HIV treatment, isn’t associated with an elevated threat of cardiovascular (CV) events. and method codes. Patients had been implemented from index time until a CV event, constant difference of 30?times without initiated ARV, a state for ATV in the ATV-free cohort,… Continue reading Background A previous cohort research indicated that atazanavir (ATV), a protease